Pfizer Stock Price, News & Analysis

ViiV Healthcare, majority owned by GSK with Pfizer (NYSE:PFE) and Shionogi as shareholders, presented new data at IAS 2025 demonstrating the effectiveness of its long-acting HIV treatments. The presentations focus on Vocabria + Rekambys (cabotegravir + rilpivirine LA) for HIV treatment and Apretude (cabotegravir long-acting) for HIV prevention.

Key highlights include the phase IIIb VOLITION study results, examining patient preferences for switching to long-acting injectables after achieving viral suppression with Dovato. Additional real-world effectiveness data from multiple studies (COMBINE-2, CARLOS, and BEYOND) demonstrate positive outcomes in various populations. Implementation studies PILLAR and EBONI show promising results for CAB LA in specific demographic groups.

The conference presentations also include new data from the Positive Perspectives wave three study, highlighting the impact of shared decision-making on treatment outcomes and patient satisfaction.

Pfizer (NYSE:PFE) announced positive topline results from the Phase 3 BASIS study of HYMPAVZI™ (marstacimab) for hemophilia A or B patients with inhibitors. The study demonstrated 93% reduction in annualized bleeding rate (ABR 1.39 vs 19.78; p < 0.0001) compared to on-demand treatment.

The trial involved 48 patients over a 12-month period, showing superiority across all bleeding-related secondary endpoints. HYMPAVZI offers a once-weekly subcutaneous injection with minimal preparation, targeting the Kunitz 2 domain of TFPI. The treatment was generally well-tolerated with no deaths or thromboembolic events reported.

This development is significant as approximately 20% of hemophilia A and 3% of hemophilia B patients develop inhibitors that render traditional factor replacement therapies ineffective.

Pfizer (NYSE:PFE) has announced its third-quarter 2025 dividend of $0.43 per share, maintaining its consistent dividend payment history. The dividend will be paid on September 2, 2025, to shareholders of record as of July 25, 2025. This marks Pfizer's 347th consecutive quarterly dividend, demonstrating the company's long-standing commitment to returning value to shareholders.

Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for August 5, 2025, at 10:00 a.m. EDT. The call will discuss the company's Second Quarter 2025 Performance Report, which will be released that morning.

Investors and the public can access the webcast through www.pfizer.com/investors. Participants can also join via phone using the following numbers: 800-456-4352 (US/Canada) or 785-424-1086 (International) with passcode "49385". The webcast replay and transcript will be available on Pfizer's website within 24 hours after the call and will remain accessible for at least 90 days.

Pfizer (NYSE: PFE) has announced a webcast discussion featuring CEO Albert Bourla at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 8:00 a.m. EDT. The webcast will be accessible through www.pfizer.com/investors, with registration details available immediately. A transcript and replay will be provided within 24 hours after the discussion and remain accessible for 90 days. The presentation may include forward-looking statements about Pfizer's operations, financial performance, product pipeline, business plans, COVID-19 response, and market dynamics, subject to risks and uncertainties as detailed in their SEC filings.

Pfizer (PFE) announced groundbreaking results from its Phase 3 BREAKWATER trial for BRAFTOVI combination therapy in treating BRAF V600E-mutant metastatic colorectal cancer. The treatment demonstrated remarkable efficacy, reducing death risk by 51% compared to standard care, with median overall survival of 30.3 months versus 15.1 months. The therapy also showed a 47% reduction in disease progression risk, with median progression-free survival of 12.8 months compared to 7.1 months. The objective response rate was significantly higher at 65.7% versus 37.4% for standard treatment. The FDA granted accelerated approval in December 2024, with potential full approval in 2025. The safety profile remained consistent with known profiles, with common side effects including nausea, anemia, and diarrhea. This breakthrough represents the first promising survival outcomes for BRAF-mutant metastatic colorectal cancer in first-line treatment.

A significant legal challenge faces Pfizer (NYSE:PFE) as a Case Management Conference is scheduled for May 30, 2025, regarding the Depo-Provera multidistrict litigation. The case involves approximately 400 lawsuits following a March 2024 British Medical Journal study showing women using Depo-Provera for over a year were 5.6 times more likely to develop intracranial meningioma. Law firm Levin Papantonio, which has secured over $80 billion in verdicts, is leading the litigation. The lawsuits allege Pfizer knew about the brain tumor risks but failed to warn U.S. consumers, despite issuing warnings in Canada (2015), UK/Europe (2024), and South Africa (2025). Studies indicate that among Depo-Provera users, approximately 2% develop brain tumors, compared to the normal rate of 40 per 10,000 women. The contraceptive, used by an estimated 74 million women globally, has a controversial history, including three FDA rejections between 1978-1992 before final approval.

Astellas and Pfizer announced significant five-year follow-up results from the Phase 3 ARCHES trial for XTANDI™ (enzalutamide) in treating metastatic hormone-sensitive prostate cancer (mHSPC). The study showed that XTANDI plus androgen deprivation therapy (ADT) reduced death risk by 30% compared to placebo plus ADT. After 61.4 months median follow-up, XTANDI plus ADT demonstrated 66% survival probability at five years versus 53% with placebo plus ADT. The drug showed particular effectiveness in high-volume disease patients, with a 36-month improvement in median overall survival. Additionally, eight-year data from the ENZAMET study revealed that XTANDI plus testosterone suppression achieved median overall survival of 8.0 years compared to 5.8 years in the control group. XTANDI has treated over one million patients globally since its 2012 approval.

Pfizer (NYSE: PFE) has secured an exclusive global licensing agreement with Chinese biotech 3SBio for SSGJ-707, a promising bispecific antibody targeting PD-1 and VEGF, excluding China market. The deal includes an upfront payment of $1.25 billion plus potential milestone payments up to $4.8 billion and tiered double-digit royalties. SSGJ-707 is currently in clinical trials for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors in China, with Phase 3 studies planned for 2025. The agreement includes Pfizer's option for China commercialization rights and a $100 million equity investment in 3SBio. Manufacturing will be conducted at Pfizer's facilities in North Carolina and Kansas. The transaction is expected to close in Q3 2025, subject to regulatory approvals and shareholder approval.